Efferon NEO Targets Pediatric Sepsis With Dual Toxin Blood Filter
Efferon NEO targets pediatric sepsis by filtering endotoxins and cytokines, with a CE mark, use in 30 countries and a planned US FDA filing coming next.
Summary
Sepsis, acute inflammation caused by infection, kills roughly 3 million children under five each year. Efferon, selected for Disrupt 2026’s Startup Battlefield 200, says its blood purification absorbers intervene when antibiotics cannot stop an immune overreaction, simultaneously removing endotoxins and cytokines. The company says this dual action, unlike other marketed devices, lowers organ failure rates and significantly speeds recovery.
Efferon makes adult absorbers, but Efferon NEO was engineered for young children’s much lower circulating blood volume. In April 2026, it received a CE mark, Europe’s counterpart to FDA approval, becoming the first multimodal blood purification device specifically designed for pediatric sepsis. It now serves intensive care units in 30 countries, including European hospitals, Saudi Arabia and Thailand. Efferon is preparing an FDA filing and expects $2 million in annualized revenue by the end of 2026. Moscow State University scientists, including co-founder Ivan Bessonov, created the technology. Serial entrepreneur and co-founder Dima Romashin became CEO earlier in 2026 to commercialize it, while acknowledging that growth trails the pace of AI startups.
Positives
- Efferon NEO received a CE mark in April 2026 as the first multimodal blood purification device engineered specifically for pediatric sepsis.
- Intensive care units in 30 countries already use Efferon NEO, including hospitals in Europe, Saudi Arabia and Thailand.
- Efferon’s mechanism simultaneously absorbs endotoxins and cytokines, which the company says reduces organ failure and accelerates recovery.
- $2 million in annualized revenue is expected by the end of 2026 as Efferon expands commercialization.
- Efferon NEO accommodates the substantially lower circulating blood volume of young children rather than adapting an adult device.
Risks & concerns
- Roughly 3 million children under five die from sepsis annually, underscoring the condition’s devastating global toll.
- Antibiotics cannot always stop the immune system’s overreaction, leaving critically ill children dependent on blood purification.
- FDA approval remains pending, with Efferon still preparing its US regulatory filing.
- No clinical trial sizes, measured effect percentages or independent validation were disclosed for Efferon’s efficacy claims.
- Dima Romashin acknowledges that Efferon is not growing at the rapid pace associated with current AI startups.